Palisade Bio Reports Additional Phase 1a/b Data Supporting Once-Daily Dosing for PALI-2108 in Ulcerative Colitis

What happened

Palisade Bio released additional Phase 1a/b data for PALI-2108, demonstrating colon-targeted PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing interval, supporting once-daily dosing in ulcerative colitis. These data reinforce the pharmacokinetic and pharmacodynamic rationale for the drug's gut-restricted profile, but they come from a small, open-label cohort not powered for efficacy. The company's single-asset story remains binary, with no product revenue and a $261M market cap pricing in significant success. While the October 2025 $138M raise funds through Phase 2 readouts in 2027-2028, the next catalysts—FSCD Phase 1b data and IND submissions—offer only modest de-risking. Investors should recognize that the current data confirm mechanism but do not reduce the substantial risk of failure in larger controlled trials.

Implication

The data support the drug's design but do not alter the fundamental risk: the stock prices a successful Phase 2 transition without randomized efficacy data. The FSCD Phase 1b topline and IND clearances due in H1 2026 are the true catalysts. Any pullback toward $1.30 improves risk/reward, but the WAIT stance remains appropriate until evidence of regulatory and operational execution is clearer.

Thesis delta

No material shift. The additional Phase 1a/b data confirm colon-targeted exposure and once-daily dosing feasibility but do not change the binary risk profile of this single-asset biotech. The investment thesis still hinges on FSCD Phase 1b data and FDA IND acceptance in H1 2026. With the stock near $1.75, upside and downside remain balanced, and the WAIT rating is reaffirmed.